ZabBio Inc.
ZabBio develops monoclonal antibody-based therapeutics targeting infectious diseases and reproductive health, with an emphasis on scalable, low-cost production for large markets. The company is developing a human contraceptive antibody formulated as a vaginal film (ZB-06); a Phase 1 clinical trial was completed in 2022 and a dose-finding Phase 2a was planned for 2024. The ZB-06 program is a collaborative, grant-funded project involving academic and industry partners.
Industries
Nr. of Employees
small (1-50)
Products
ZB-06 (human contraceptive antibody)
A human monoclonal antibody formulated as a vaginal film intended for on-demand female contraception. The antibody agglutinates sperm and traps sperm in cervical mucus to prevent ascent and fertilization.
ZB-06 (human contraceptive antibody)
A human monoclonal antibody formulated as a vaginal film intended for on-demand female contraception. The antibody agglutinates sperm and traps sperm in cervical mucus to prevent ascent and fertilization.
Expertise Areas
- Monoclonal antibody development
- Contraceptive product development
- Reproductive health therapeutics
- Early-phase clinical trials
Key Technologies
- Monoclonal antibody therapeutics
- Vaginal film drug delivery
- Antibody-mediated agglutination mechanisms
- Clinical trial operations (Phase 1/2a)
News & Updates
Press release announcing IND opening for the contraceptive antibody program.
News item linking to external coverage about antibody development for acute flaccid myelitis.
Phase 1 clinical trial of the contraceptive antibody formulated as a vaginal film was completed in 2022 at the Jones Institute for Reproductive Medicine (EVMS).
ZB-06 program is funded by an NICHD Contraceptive Research Center grant (2P50HD096957-02) and conducted in collaboration with academic and industry partners.
Press release announcing IND opening for the contraceptive antibody program.
News item linking to external coverage about antibody development for acute flaccid myelitis.
Phase 1 clinical trial of the contraceptive antibody formulated as a vaginal film was completed in 2022 at the Jones Institute for Reproductive Medicine (EVMS).
ZB-06 program is funded by an NICHD Contraceptive Research Center grant (2P50HD096957-02) and conducted in collaboration with academic and industry partners.